Search

Displaying results 2471 - 2480 of 10000 in total
  1. Drug

    Testosterone cypionate

    go.drugbank.com/drugs/DB13943
    ApprovedInvestigational

    Testosterone cypionate is a synthetic derivative of testosterone in the form of an oil-soluble 17 (beta)-cyclopentylpropionate ester. … It was developed by the company Pharmacia and Upjohn and FDA approved on July 25, 1979.

  2. Drug

    Norepinephrine

    go.drugbank.com/drugs/DB00368
    ApprovedInvestigational

    It is also found in plants and is used pharmacologically as a sympathomimetic. … Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers and of the diffuse projection system in the brain arising from the locus ceruleus.

    Products: N-EPI, Norepinephrine Bitartrate In Sodium Chloride
  3. Drug

    Ethylhexyl methoxycrylene

    go.drugbank.com/drugs/DB11226
    Approved

    It currently enjoys regional approvals in Canada, the EU, and the US [L2847]. … It is used as a solvent for crystalline UV filters and is easily emulsified and suitable for use in various lotions, creams, sprays, sticks, and gel formulations [F104].

  4. Drug

    Ospemifene

    go.drugbank.com/drugs/DB04938
    Approved

    FDA approved on February 26, 2013.

  5. Drug

    Melphalan flufenamide

    go.drugbank.com/drugs/DB16627
    ApprovedWithdrawn

    It has since been withdrawn from the market in the wake of the phase 3 OCEAN trial which showed a decrease in overall survival in comparison to standard treatment with [pomalidomide] and [dexamethasone … [A230143,L32173] Melphalan flufenamide was granted FDA approval on 26 February 2021.[L32173].

  6. Drug

    Crinecerfont

    go.drugbank.com/drugs/DB18518
    ApprovedInvestigational

    [A264818] Crinecerfont was approved by the FDA in December 2024 as an adjunct to glucocorticoid replacement in patients with CAH.[L51973,L51993] … [A264818] The majority of the poor health outcomes in patients with CAH result from the inability to precisely titrate glucocorticoid dosages to both adequately replace the deficiency and sufficiently

  7. Drug

    Beractant

    go.drugbank.com/drugs/DB06761
    Approved

    Administration of lung surfactant remains the cornerstone of therapy in this condition that is currently the leading cause of death in preterm infants. … It is suspended in 0.9% sodium chloride solution, and heat-sterilized.

  8. Drug

    Gemtuzumab ozogamicin

    go.drugbank.com/drugs/DB00056
    ApprovedInvestigational

    in combination with chemotherapy or on its own [L941]. … The antibody is specifically directed against the CD33 antigen present on leukemic myeloblasts in most patients with acute myeloid leukemia (AML).

  9. Drug

    Efmoroctocog alfa

    go.drugbank.com/drugs/DB11607
    ApprovedInvestigational

    in the patient populations being studied [A31551]. … It is an antihemorrhagic agent used in replacement therapy for patients with haemophilia A (congenital factor VIII deficiency). It is suitable for all age groups.

  10. Drug

    Casein

    go.drugbank.com/drugs/DB10516
    Approved

    Casein allergenic extract is used in allergenic testing.

    Categories: Compounds used in a research, industrial, or household setting